Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Januar 2023 - 10:05PM
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or
“Viridian”), a biopharmaceutical company focused on discovering and
developing potential best-in-class medicines for serious and rare
diseases, today announced that a majority of the independent
directors serving on the Compensation Committee of the Company’s
Board of Directors approved the grant of non-qualified stock
options to an employee to purchase up to 35,000 shares of the
Company’s common stock (the “Inducement Grant”) on January 3, 2023
(the “Grant Date”). The Inducement Grant has been granted outside
of the Company’s Amended and Restated 2016 Equity Incentive Plan
(the “Plan”) but remains subject to the terms and conditions of
such Plan. The Inducement Grant was granted as an inducement
material to this individual entering into employment with Viridian
in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is
equal to the closing price of Viridian’s common stock on the Grant
Date. The Inducement Grant will vest over a four-year period, with
25% of the shares vesting on the one-year anniversary of the
employee’s start date, and thereafter the remainder of the shares
vest in 36 equal monthly installments, subject to the employee’s
continued employment with Viridian through the applicable vesting
dates.
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company
focused on engineering and developing potential best-in-class
medicines for patients with serious and rare diseases. Viridian’s
expertise in antibody discovery and engineering enables it to
develop differentiated therapeutic candidates for previously
validated drug targets in commercially established disease
areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The Company
recently initiated its first global Phase 3 trial called ‘THRIVE’
to evaluate the safety and efficacy of VRDN-001 in patients with
active TED. Viridian is also evaluating VRDN-001 in a Phase 2
proof-of-concept trial in patients with chronic TED. In addition to
its intravenously administered VRDN-001 program, the Company is
advancing two candidates for its subcutaneous strategy with the
goal of providing a more conveniently administered therapy to
patients with TED. Viridian is developing multiple preclinical
assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn.
Investor and Media Contact:
Todd JamesViridian Therapeutics, Inc.Senior Vice President,
Corporate Affairs and Investor
RelationsIR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024